publication venue for Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors.. 11. 2022 Theranos Experience Exposes Weaknesses in FDA Regulatory Discretion.. 6. 2017